These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8791019)

  • 1. Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
    Tashiro K; Goto I; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Ogawa N; Yanagisawa N
    Eur Neurol; 1996; 36 Suppl 1():32-7. PubMed ID: 8791019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nine-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
    Kowa H; Kanazawa I; Goto I; Kuno S; Mizuno Y; Ogawa N; Tashiro K; Yanagisawa N
    Eur Neurol; 1997; 38 Suppl 1():23-8. PubMed ID: 9276197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine therapy in early-stage Parkinson's disease.
    Fukuyama H; Kawamura J; Akiguchi I; Kimura J; Imai T
    Eur Neurol; 1996; 36(3):164-70. PubMed ID: 8738948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress note on Japanese multicenter bromocriptine monotherapy.
    Kuno S
    Eur Neurol; 1993; 33 Suppl 1():3-5. PubMed ID: 8375429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
    Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
    Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: analysis on the maintenance and the change of the original mode of treatment.
    Nakanishi T; Kanazawa I; Iwata M; Goto I; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1992; 32 Suppl 1():23-9. PubMed ID: 1425818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations.
    Giménez-Roldán S; Mateo D
    Clin Neuropharmacol; 1994 Oct; 17(5):435-44. PubMed ID: 9316693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    Ramaker C; Hilten JJ
    Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The new Parkinson's disease drugs].
    Hasegawa K
    Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.